Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis

Iron homeostasis is dysregulated in primary myelofibrosis (PMF), given the high prevalence of anemia, need for red blood cell (RBC) transfusions, and disease‐associated inflammatory state. We measured plasma hepcidin levels in 203 consecutive PMF patients at the time of first referral; hepcidin levels were significantly higher as compared to healthy controls (P < 0.0001), and were correlated with hemoglobin of <10 g/dL, RBC transfusion requirement, serum ferritin of >500 µg/L, higher dynamic international prognostic scoring system (DIPSS)‐plus risk category, the presence of circulating blasts, age of >65 years, and leukocyte count of <4 × 109/L. Increased hepcidin levels predicted for inferior survival independent of six out of the eight DIPSS‐plus prognostic parameters (hazard ratio [HR] = 1.8; P = 0.02), but not when RBC transfusion requirement, hemoglobin of <10 g/dL, or increased serum ferritin were included in the Cox model. Multivariable analysis that considered the four overlapping prognostic variables revealed that increased hepcidin (HR = 1.9; P = 0.03) and increased ferritin (HR = 2.3; P = 0.04), but not hemoglobin of <10 g/dL or RBC transfusion requirement, independently retained their significance for predicting survival. Accordingly, increased levels of both hepcidin and serum ferritin (seen in 29% of patients) predicted inferior survival independent of DIPSS‐plus or increased inflammatory cytokine levels (HR = 2.4; P = 0.002), and could be considered in future prognostic models for PMF. Am. J. Hematol. 88:312–316, 2013. © 2013 Wiley Periodicals, Inc.

[1]  Zhen-Zhen Sun,et al.  Hepcidin expression in patients with acute leukaemia , 2012, European journal of clinical investigation.

[2]  Herbert Y. Lin,et al.  Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation , 2012, American journal of hematology.

[3]  A. Tefferi,et al.  One thousand patients with primary myelofibrosis: the mayo clinic experience. , 2012, Mayo Clinic proceedings.

[4]  M. Muckenthaler,et al.  Second Round Robin for plasma hepcidin methods : First steps toward harmonization , 2012 .

[5]  M. Cazzola,et al.  Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem‐cell transplantation: Report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo , 2011, American journal of hematology.

[6]  Tomas Ganz,et al.  Hepcidin and iron regulation, 10 years later. , 2011, Blood.

[7]  A. Tefferi,et al.  Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. Passamonti,et al.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Girelli,et al.  Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes , 2010, PloS one.

[10]  A. Tefferi,et al.  Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients , 2010, Leukemia.

[11]  Pan-pan Cheng,et al.  Hepcidin expression in anemia of chronic disease and concomitant iron-deficiency anemia , 2011, Clinical and Experimental Medicine.

[12]  Ayalew Tefferi,et al.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.

[13]  Matthias W. Hentze,et al.  Two to Tango: Regulation of Mammalian Iron Metabolism , 2010, Cell.

[14]  Dominica H. C. Wong,et al.  Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy , 2009, Hematological oncology.

[15]  V. Pullarkat Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? , 2009, Blood.

[16]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[17]  T. Ganz,et al.  Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis , 2008, British journal of haematology.

[18]  S. Goh,et al.  High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin , 2007, Nature Medicine.

[19]  A. Tefferi,et al.  Clinical correlates of JAK2V617F allele burden in essential thrombocythemia , 2007, Cancer.

[20]  T. Ganz,et al.  Liver iron concentrations and urinary hepcidin in beta-thalassemia. , 2007, Haematologica.

[21]  Jerry Kaplan,et al.  Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization , 2004, Science.